Back to results
US 12,760,077 B2Granted
T-cell mobilizing CXCL10 mutant with increased glycosaminoglycan binding affinity
AssigneeAntagonis Biotherapeutics GmbH
InventorAndreas Kungl
Life of this patent
Estimating the term…
Abstract
Herein provided is a novel recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10 and increasing T-cell mobilization and its use for preventing or treating inflammatory and immunological disorders and auto-immune diseases.
Claims16
A recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10, comprising an amino acid sequence having at least 95% sequence identity with SEQ ID NO:
- 1, wherein the amino acid sequence at position 20 of SEQ ID NO:
- 1 is substituted with lysine, and optionally wherein the amino acid sequence at positions 12, 14, or 25 of SEQ ID NO:
- 1 is further substituted with lysine.
Dependencies are inferred from the claim text.